Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis

Last updated: March 27, 2025
Sponsor: AO Innovation Translation Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lung Cancer

Musculoskeletal Diseases

Bone Diseases

Treatment

Surgical Resection and Reconstruction

Clinical Study ID

NCT04098146
SMDR Registry
  • Ages > 18
  • All Genders

Study Summary

Prospective will be collected in a minimum of 300 patients presenting with an acquired segmental mandibular defect ≥ 2 cm secondary to OSSC removal and drugs-induced osteonecrosis, and who require mandibular reconstruction.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • The study includes patients with an initial pathological/histologic diagnosis ofmandibular involvement by oral tumors (such as OSCC, osteosarcoma, andameloblastoma), bisphosphonate- or immunomodulatory drug-induced osteonecrosis, andmandibular lesions from metastatic conditions originating from other sites includinglung, breast, prostate, or kidney.

  • Age 18 years and older

  • Bisphosphonate related osteonecrosis of the mandible

  • Immunomodulatory drugs induced mandibular osteonecrosis

  • Patients presented with ameloblastoma affecting the mandible

  • Patients presented with osteosarcomas of the mandible

  • Patients presented with oral metastases related mandibular lesions that areindicated for segmental resection, common primary tumor sites include lung, breast,prostate and kidney

  • Undergoing primary curative treatment with segmental resection of the mandible ≥2 cm

  • Intention to undergo mandibular reconstruction with autologous bone using a primary (one-stage) or secondary (two-stage) approach

  • Informed consent obtained, ie:

  • Ability to understand the content of the patient information/ICF

  • Willingness and ability to participate in the clinical investigation accordingto the registry plan (RP) o Signed and dated IRB/EC approved ICF OR

  • Written consent provided according to the IRB/EC defined and approvedprocedures for patients who are not able to provide to provide independentwritten informed consent

Exclusion

Exclusion Criteria:

  • Tumors affecting the condyle

  • Patients under palliative care

  • Previous extensive mandibular surgeries (including reconstructions, e.g., TMJreplacement) that may potentially confound the outcome measures

Intraoperative exclusion criteria:

  • Nonsegmental mandibular defect (eg. box resection/partial resection)

  • Segmental mandibular defect of less than 2 cm

  • Mandibular defects extending beyond the sigmoid notch into the condyles

Additional exclusion criterion:

• No osseous reconstruction with autologous bone performed within 18 months from resection

Study Design

Total Participants: 300
Treatment Group(s): 1
Primary Treatment: Surgical Resection and Reconstruction
Phase:
Study Start date:
September 12, 2022
Estimated Completion Date:
December 31, 2030

Study Description

Data will be prospectively collected from at least 300 patients with acquired segmental mandibular defects of 2 cm or larger following resection of tumors or necrotic/infected tissue, all of whom require mandibular reconstruction.

The follow up (FU) will consist of standard of care (routine) procedures and data collection will be done at 3, 6, 12, 18 and up to 24 months after resection and/or reconstruction. The maximum FU for each patient within the registry will be 2 years after mandibular resection.

Data collection will include confounding baseline data, tumor characteristics, neurological function, patient reported outcomes, quality of life as well as anticipated procedure-related adverse events (AEs). Available images will be collected and evaluated centrally to determine the location, positioning, osseointegration, bone quantity and quality of the transplants.

Depending on the volume and quality of the collected data, different statistical analyses will be performed. Exploratory analyses will be conducted to find relationships between the different treatment modalities and their outcomes.

Connect with a study center

  • Medical University of Graz

    Graz, 8036
    Austria

    Site Not Available

  • Universitätsklinikum Tübingen

    Tübingen, Baden-Württemberg 72076
    Germany

    Active - Recruiting

  • University Hospital RWTH Aachen

    Aachen, 52074
    Germany

    Active - Recruiting

  • University Hospital Charité

    Berlin, 13353
    Germany

    Active - Recruiting

  • Hannover Medical School

    Hannover, 30625
    Germany

    Active - Recruiting

  • Universitätsklinikum Heidelberg

    Heidelberg, 69120
    Germany

    Active - Recruiting

  • University Hospital Leipzig

    Leipzig, 04103
    Germany

    Active - Recruiting

  • Klinikum der LMU München

    Munich, 80337
    Germany

    Active - Recruiting

  • Erasmus University Medical Centre

    Rotterdam, 3015 GD
    Netherlands

    Active - Recruiting

  • National Medical and Surgical Center

    Moscow, 125284
    Russian Federation

    Site Not Available

  • 12 de Octubre

    Madrid, 28041
    Spain

    Active - Recruiting

  • Uppsala University Hospital

    Uppsala, 75185
    Sweden

    Active - Recruiting

  • University Hospital Basel

    Basel, 4031
    Switzerland

    Active - Recruiting

  • University of California

    Sacramento, California 95817
    United States

    Site Not Available

  • University of Florida College of Medicine

    Jacksonville, Florida 32209
    United States

    Active - Recruiting

  • University of Illinois Chicago

    Chicago, Illinois 60612
    United States

    Active - Recruiting

  • Mount Sinai Hospital

    New York, New York 10029
    United States

    Active - Recruiting

  • John Peter Smith Health Network

    Fort Worth, Texas 76104
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.